BeiGene company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

beigene.com

Total Raised

$177M

Investors Count

10

Deal Terms

1

Investments

4

BeiGene Funding, BeiGene Valuation & BeiGene Revenue

10 Fundings

BeiGene's latest funding round was a IPO - II for $3,500M on November 30, 2021.

BeiGene's valuation in October 2019 was $13,170.73M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/30/2021

IPO - II

$3,500M

0

FY undefined

24

10/6/2020

PIPE - II

$28.72M

0

FY undefined

1

7/13/2020

Corporate Minority - P2P - II

$421M

0

FY undefined

1

7/13/2020

PIPE

$99M

0

FY undefined

10

10/31/2019

Corporate Minority - P2P

$99M

$13,170.73M

0

FY undefined

10

Date

11/30/2021

10/6/2020

7/13/2020

7/13/2020

10/31/2019

Round

IPO - II

PIPE - II

Corporate Minority - P2P - II

PIPE

Corporate Minority - P2P

Amount

$3,500M

$28.72M

$421M

$99M

$99M

Investors

Valuation

$13,170.73M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

24

1

1

10

10

Financials

Income Statement

Income Statement

12/31/2021

12/31/2020

12/31/2019

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2021

12/31/2020

12/31/2019

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2021

12/31/2020

12/31/2019

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

BeiGene Deal Terms

1 Deal Term

BeiGene's deal structure is available for 1 funding round, including their Corporate Minority - P2P from October 31, 2019.

Round

Corporate Minority - P2P

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Corporate Minority - P2P

$99M

$99M

$99M

$99M

$99M

$99M

BeiGene Investors

10 Investors

BeiGene has 10 investors. Get Finance Holdings invested in BeiGene's PIPE - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/6/2020

10/6/2020

1
PIPE - II

Holding Company

China

11/14/2014

7/13/2020

3
Private Equity, Private Equity - II (2015), PIPE (2020)

Asset/Investment Management

China

10/31/2019

7/13/2020

2
Corporate Minority - P2P, Corporate Minority - P2P - II (2020)

Corporation

California

00/00/0000

00/00/0000

CITIC Capital

Subscribe to see more

Private Equity

Hong Kong

00/00/0000

00/00/0000

Rock Springs Capital

Subscribe to see more

Hedge Fund

Maryland

First funding

10/6/2020

11/14/2014

10/31/2019

00/00/0000

00/00/0000

Last Funding

10/6/2020

7/13/2020

7/13/2020

00/00/0000

00/00/0000

Investor

CITIC Capital

Rock Springs Capital

Rounds

1
PIPE - II
3
Private Equity, Private Equity - II (2015), PIPE (2020)
2
Corporate Minority - P2P, Corporate Minority - P2P - II (2020)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Holding Company

Asset/Investment Management

Corporation

Private Equity

Hedge Fund

Location

China

China

California

Hong Kong

Maryland

BeiGene Investments

4 Investments

BeiGene has made 4 investments. Their latest investment was in Shoreline Biosciences as part of their Series B on November 11, 2021.

CBI Logo

BeiGene Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/3/2021

Series B

Shoreline Biosciences

$140M

Yes

6

6/23/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/17/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/3/2020

PIPE

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

6/23/2021

3/17/2021

1/3/2020

Round

Series B

Series A

Series A

PIPE

Company

Shoreline Biosciences

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$140M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

10

10

10

You May Also Like

G
Guangzhou Baiyunshan Pharmaceutical

Guangzhou Baiyunshan Pharmaceutical specializes in the development and production of Chinese patent medicines, biological products, health medicines, and health beverages, as well as the wholesale, retail, import, and export of Chinese medicine, western medicine, and medical equipment. It is based in Guangzhou, Guangdong.

D
Delova Biotech

Delova Biotech is a specialty branded pharmaceutical company, focusing on the development of proprietary formulations of injectable drug products to fulfill unmet medical needs in China and the US. The firm was founded in 2017 and is based in Nanjing, China.

H
Hua Medicine

Hua Medicine (华领医药) (HK: 02552) is a clinical-stage drug development company in China, focusing on therapies for the treatment of diabetes and CNS disorders.

Sinopharm Logo
Sinopharm

China National Pharmaceutical Group is a Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC). Sinopharm's core businesses include distribution, retail, scientific research, and manufacture of healthcare-related products and owns wholly-owned or holding subsidiaries, and companies, including Sinopharm Group, China National Medicines, Sinopharm Accord Medicines, Tiantan Biological Products, Shanghai Shyndec Pharmaceutical, and China Traditional Chinese Medicine.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.